Reckitt Benckiser Group PLC (OTCMKTS:RBGLY - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $15.20, but opened at $14.55. Reckitt Benckiser Group shares last traded at $15.15, with a volume of 14,307 shares trading hands.
Analyst Upgrades and Downgrades
RBGLY has been the topic of a number of recent analyst reports. Royal Bank Of Canada restated an "outperform" rating on shares of Reckitt Benckiser Group in a research report on Friday, July 25th. Sanford C. Bernstein upgraded shares of Reckitt Benckiser Group from a "hold" rating to a "strong-buy" rating in a research report on Thursday, June 5th. Four investment analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy".
Check Out Our Latest Stock Report on RBGLY
Reckitt Benckiser Group Stock Down 1.3%
The company has a debt-to-equity ratio of 1.01, a current ratio of 0.56 and a quick ratio of 0.37. The stock's 50 day simple moving average is $14.40 and its two-hundred day simple moving average is $13.67.
Reckitt Benckiser Group Cuts Dividend
The business also recently announced a dividend, which will be paid on Thursday, September 25th. Shareholders of record on Monday, August 11th will be paid a $0.2106 dividend. The ex-dividend date of this dividend is Friday, August 8th. This represents a dividend yield of 341.0%.
About Reckitt Benckiser Group
(
Get Free Report)
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
Further Reading
Before you consider Reckitt Benckiser Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Reckitt Benckiser Group wasn't on the list.
While Reckitt Benckiser Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.